Neuland Laboratories Limited

NSE NEULANDLAB.NS

Neuland Laboratories Limited Goodwill for the year ending March 31, 2024: USD 33.50 M

Neuland Laboratories Limited Goodwill is USD 33.50 M for the year ending March 31, 2024, a -1.46% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.
  • Neuland Laboratories Limited Goodwill for the year ending March 31, 2023 was USD 34.00 M, a -7.62% change year over year.
  • Neuland Laboratories Limited Goodwill for the year ending March 31, 2022 was USD 36.81 M, a -3.57% change year over year.
  • Neuland Laboratories Limited Goodwill for the year ending March 31, 2021 was USD 38.17 M, a 2.92% change year over year.
  • Neuland Laboratories Limited Goodwill for the year ending March 31, 2020 was USD 37.08 M, a -7.78% change year over year.
Key data
Date Goodwill Total Assets Current Liabilities Total Non-Current Liabilities
Market news
SV Wall Street
NSE: NEULANDLAB.NS

Neuland Laboratories Limited

CEO Mr. Davuluri Sucheth Rao
IPO Date Oct. 13, 2008
Location India
Headquarters Phoenix IVY Building
Employees 1,643
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Plastics
Description

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.

StockViz Staff

February 2, 2025

Any question? Send us an email